With over 15yrs of pharmaceutical and research experience, Holly is a seasoned executive who leverages her global knowledge of drug development across preclinical and clinical trials, including regulated bioanalytical and toxicology services across multiple species.
Prior to joining Agilex, Holly has experience in Phase I-IV across multiple indications, with a primary focus on early phase clinical development in Australia & New Zealand. She has held various leadership roles, including working in a phase I clinical research unit in Overland Park, Kansas, director of clinical operations in small oncology biotech, and in 2018 transferred to Sydney, Australia where she has extensive knowledge in guiding emerging biotechs in US, APAC and EU to navigate the requirements for conducting clinical trials in Australia.
Holly is passionate about bringing new life-transforming molecules to market to save lives. This includes driving excellence in bioanalytical and toxicology services for new medicines where there aren’t any solutions and driving successful clinical outcomes.